In addition, Qianshan Pharmaceutical Machinery Co., Ltd. and Zhongzhuang Construction Co., Ltd. also saw a significant decline. The latest number of shareholders decreased by 10.82% and 10.43% respectively compared with the previous period.
Chips are mainly distributed in mechanical equipment, electronics, chemical industry and electrical equipment industries, with 20, 15, 11 and 10 chips respectively. From the perspective of market performance, since May 6, the share price of 94 chips has risen, accounting for 65% of the total number of chips. Desai battery, seagull residential industry, Huangshanghuang, zhongchong stock and investment surplus have performed well, with the share price rising more than 20%.
In terms of the average stock market value of the chip concentrated shares, the average stock market value of 14 shareholders is more than 1 million yuan. Average market value of shareholders of Zhuosheng micro three hundred and thirty-nine point eight seven Million yuan ranked first, and other households with higher stock market value are Huichuan technology, investment surplus, Shuanghui development, and Meiya optoelectronics. The stock market value of each household has exceeded 2 million yuan.
According to the statistics of databao, the number of shareholders has declined 47 shares in three consecutive periods. Beirui gene has the largest decline, with the latest number of shareholders of 15402, down 26.16% compared with the number before the third phase; the next is precision electronics, down 25.79% compared with the number before the third phase; other shareholders have a large decline, such as wangneng environment, Huichuan technology, Jiejia Weichuang, Huaxi Co., Ltd., zhongchong Co., Ltd., etc.
Berry genes main business is gene detection service and equipment reagent sales based on sequencing. Fujian gene, a wholly-owned subsidiary of the company, was appointed as a third-party testing agency responsible for nucleic acid testing of confirmed cases, suspected cases and close contacts, the company said on May 12. At present, the companys nucleic acid test kit is only for domestic epidemic situation, and is not involved in export temporarily. At present, the epidemic screening in China is relatively stable. For example, Wuhan has carried out a general epidemic screening covering all the population, which requires a large amount of nucleic acid testing; overseas epidemic is still spreading, and there is a large demand for nucleic acid testing. Once the export qualification is obtained, the space for performance growth will be opened.
Under the attack of the epidemic, if individual stocks can still remain profitable in the first quarter of this year, it shows their resilience in profitability. Of the 147 shares with lower number of shareholders on a month on month basis, 16 were less than 40 times of the estimated value, and the growth rate of net profit attributable to the parent exceeded 10% in the first quarter of this year.
From the valuation level, the rolling P / E ratio of Jinneng technology is 7.83 times, and the rolling P / E ratio of Tianneng heavy industry, Zhongyuan environmental protection, Daijin heavy industry, Tiankang biology, wangneng environment and other stocks is not high, not more than 20 times. From the perspective of market performance, 13 shares rose better than the same period of the Shanghai index, accounting for more than 80%.
According to the first quarter performance, the net profit of 8 shares attributable to the parent company increased by more than 50%. Among them, the growth rate of net profit attributable to the parent of Tiankang biology in the first quarter was more than 10 times, far more than other stocks; other stocks with double performance were Daikin heavy industry and Yifan medicine, up 338.37% and 119.79% respectively.
Statement: all information content of data treasure does not constitute investment advice. The stock market is risky and investment should be cautious.